Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists

Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists

A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. P...

Full description

Bibliographic Details
Main Authors: I. I. Dedov, N. G. Mokrysheva, M. V. Shestakova, T. V. Nikonova, A. Yu. Mayorov, G. R. Galstyan, M. Sh. Shamhalova, V. O. Barysheva, A. S. Ametov, M. B. Antsiferov, A. Yu. Babenko, T. P. Bardymova, F. V. Valeeva, A. A. Vachugova, E. N. Grineva, T. Yu. Demidova, T. P. Kiseleva, M. A. Kunicyna, T. N. Markova, A. M. Mkrtumyan, N. A. Petunina, L. A. Ruyatkina, V. V. Saluhov, L. A. Suplotova, E. L. Hadarceva, Yu. Sh. Halimov
Format: Article
Language:English
Published: Endocrinology Research Centre 2022-03-01
Series:Сахарный диабет
Subjects:
type 2 diabetes mellitus
covid-19
antihyperglycemic therapy
Online Access:https://www.dia-endojournals.ru/jour/article/view/12873

Internet

https://www.dia-endojournals.ru/jour/article/view/12873

Similar Items